✦ LIBER ✦

Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1) : A clinical Phase II study

✍ Scribed by Thomas Otto; Axel Bex; Susanne Krege; Peter H. Walz; Herbert Rübben

Publisher: John Wiley and Sons
Year: 1997
Tongue: English
Weight: 148 KB
Volume: 80
Category: Article
ISSN: 0008-543X
DOI: 10.1002/(sici)1097-0142(19970801)80:3<465::aid-cncr14>3.0.co;2-v

No coin nor oath required. For personal study only.

✦ Synopsis

and an antimotility factor (acellular pertussis vaccine [APV]) in 18 School, Essen, Germany.

patients with cisplatin-and methotrexate-resistant metastatic bladder carcinoma.

Intramuscular injection of APV 3 times in the first week, on Days 1, 4, and 7, was

📜 SIMILAR VOLUMES

Phase II study of pemetrexed disodium, a

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma : A study of the national cancer institute of Canada clinical trials group

✍ Frances A. Shepherd; Janet Dancey; Andrew Arnold; Alan Neville; James Rusthoven; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 2 views

## Background: Pemetrexed disodium (alimta [eli lilly and company, indianapolis, in], ly231514, multitargeted antifolate) is a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway. phase ii trials showed single-agent response rates of 16% and 23% in untreated pati